-
冠心病是影响人类健康的严重疾病,多种危险致病因素已经明确,包括吸烟、高血压、高血脂、高血糖等。近年来,国内外学者仍致力于冠心病患病机制的研究,发现甲状腺激素在机体的多种器官中发挥重要作用,其代谢的异常不仅可以导致甲状腺功能亢进,还能引起不同种类的心脏疾病[1],是冠心病的重要危险因素[2-3]。
目前,甲状腺激素水平与冠心病的关系仍然存在争议,本研究通过对冠状动脉造影证实的冠状动脉狭窄与无狭窄患者对比,进行多种危险因素分析,观察甲状腺激素水平与冠心病及其病变严重程度的关系。
-
冠心病冠脉狭窄各组与冠脉无狭窄组基本资料分析结果见表 1。4组患者的年龄、LDL-C、TC以及吸烟史、高血压史、脑卒中史之间的差异无统计学意义。与对照组相比,单支病变组患者的糖尿病患病率、fT4水平显著增高(t=1.557、3.026,P均 < 0.05),HDL-C水平显著降低(t=1.957,P < 0.05),双支病变组与多支病变组患者的fT3水平显著降低(t=1.947,6.415,P < 0.05)。与单支病变组比较,多支病变组的fT3、FBG、左心室射血分数(left ventricular ejection fraction,LVEF)水平出现差异(t=0.567、0.649、1.032,P均 < 0.05);双支病变组差异无统计学意义。与双支病变组比较,多支病变组的fT3、FBG和LVEF水平的降低差异具有统计学意义(t=2.992、1.736、2.481,P均 < 0.05)。
组别 例数 年龄
(x±s,岁)性别
(男/女)吸烟史
(n,%)糖尿病史
(n,%)高血压史
(n,%)脑卒中史
(n,%)fT3
(pmol/L)fT4
(x±s,pmol/L)TSH
(x±s,pmol/L)TC
(x±s,mmol/L)LDL-C
(x±s,mmol/L)HDL-C
(x±s,mmol/L)TG
(mmol/L)FBG
(mmol/L)LVEF
(x±s,%)冠脉无狭窄组 98 61.3±11.2 43/55 17(17.3) 14(14.3) 76(77.6) 14(14.3) 0.68
(4.06~5.49)16.49±3.13 2.87±1.16 4.99±1.13 3.09±0.93 1.13±0.39 0.17
(1.07~2.02)0.72
(4.77~5.63)59.05±5.79 单支病变组 30 65.1±11.3 17/13 9(30.0) 9(30.0) 25(83.3) 7(23.3) 0.65
(3.98~4.75)18.08±2.31 2.58±1.07 4.67±1.45 3.03±1.31 0.99±0.22 0.13
(1.06~1.61)0.75
(4.96~5.87)58.07±5.67 双支病变组 15 66.2±6.9 7月8日 2(13.3) 5(33.3) 12(80.0) 3(20.0) 0.63
(3.77~4.96)17.49±2.72 2.83±1.00 4.63±1.41 2.83±0.92 1.02±0.34 0.14
(0.90~2.23)0.76
(3.96~8.71)56.07±6.97 多支病变组 15 66.5±11.7 11月4日 5(33.3) 6(40.0) 14(93.3) 2(13.3) 0.55
(3.21~3.87)17.81±3.47 3.97±0.93 4.43±0.77 3.97±0.93 0.89±0.18 0.28
(1.17~3.46)0.73
(3.91~5.33)48.53±9.47 注:表中,fT3为游离三碘甲腺原氨酸,fT4为游离甲状腺素,TSH为促甲状腺激素,TC为总胆固醇,TG为三酰甘油,LDL-C为低密度脂蛋白胆固醇,HDL-C为高密度脂蛋白胆固醇,FBG为空腹血糖,LVEF为左心室射血分数。 表 1 冠心病冠脉狭窄各组与冠脉无狭窄组基本资料分析
-
以性别、年龄、血脂水平、糖尿病史、高血压史、吸烟史、脑卒中史、fT3、fT4、TSH作为自变量,冠脉病变支数作为因变量,采用多个模型进行Logistic回归分析,结果见表 2。在模型1(因变量:对照组=0,冠脉狭窄=1)的分析中,发现fT3降低、高龄和糖尿病史是发生冠心病的危险因素;在模型2(因变量:对照组=0,冠脉狭窄单支病变=1)的分析中,仅有糖尿病史是发生冠心病的危险因素;在模型3(因变量:对照组=0,冠脉狭窄双支病变=1)的分析中未发现与冠心病相关的因素;在模型4(因变量:对照组=0,冠脉病变多支狭窄=1)的分析中,糖尿病史和fT3降低是发生冠心病的危险因素。
变量 OR(95%CI) P值 模型1 fT3 0.447(0.277~0.723) 0.001 年龄 1.053(1.012~1.096) 0.011 糖尿病史 4.932(1.521~15.997) 0.008 模型2 fT3 0.561(0.312~-1.010) 0.054 糖尿病史 4.422(1.332~-14.682) 0.015 模型3 fT3 0.499(0.231~-1.080) 0.078 模型4 fT3 0.085(0.013~-0.570) 0.011 糖尿病史 13.149(1.154~-149.83) 0.038 注:表中,OR为危险度比值;95%CI为95%可信度区间;fT3为游离三碘甲腺原氨酸。 表 2 冠心病患者危险因素Logistic回归分析
-
以性别、年龄、fT3、fT4、TSH、TG、TC、HDL-C、LDL-C、糖尿病史、高血压史等为自变量,Gensini评分为因变量进行多元逐步回归分析,发现fT3与Gnesini评分呈负相关(β值=-0.234,t=2.871,P < 0.01)。fT3每降低0.234 pmol/L,Gensini评分升高1分。
甲状腺功能与冠脉病变程度的相关性研究
Correlation between thyroid function and the severity of coronary artery disease
-
摘要:
目的 探讨甲状腺激素水平与冠心病及其严重性的关系。 方法 冠心病患者158例,根据选择性冠状动脉造影证实冠脉病变狭窄程度,将其分为冠脉狭窄组60例和冠脉无狭窄组(对照组)98例,再将冠脉狭窄组按狭窄累及范围分为单支病变组30例、双支病变组15例和多支(3支以上)病变组15例。采用电化学发光法检测游离三碘甲腺原氨酸(fT3)、游离甲状腺素(fT4)和促甲状腺激素(TSH)水平;采用胆固醇氧化酶法测定高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)等指标。采用Gensini评分来评价受试者冠脉狭窄程度。 结果 与对照组比较,冠脉狭窄的双支病变组和多支病变组患者fT3水平显著降低(t=1.947、6.415,P均 < 0.05),冠脉狭窄单支病变组fT4水平显著升高(t=3.026,P < 0.05)。采用Logistic回归分析发现,fT3是冠心病的独立危险因素。以Gensini评分为因变量进行多元线性回归分析发现,fT3与Gensini评分呈负相关,fT3每降低0.234 pmol/L, Gensini评分升高1分。 结论 fT3水平在冠状动脉狭窄患者中显著降低,并且与冠心病的严重程度密切相关,是冠心病的独立危险因素;fT3每降低0.234 pmol/L, Gensini评分升高1分,可以作为冠心病风险增加的敏感指标。 Abstract:Objective To explore the correlation between thyroxine hormone and the severity of coronary artery disease(CAD). Methods 158 patients with coronary adisease were entered consecutively into the study. They were separated into control group(absence of CAD, n=98)and CAD group(presence of CAD, n=60). Based on the number of vessel disease, CAD group was further divided into three sub-groups:single-vessel CAD subgroup(n=30), bi-vessel CAD subgroup(n=15) and multi-vessel CAD subgroup(n=15). Serum free triiodothyronine(fT3), free thyroxine(fT4), thyroid stimulating hormone(TSH) were tested by electrochemiluminescence; high density lipoprotein cholesterol(HDL-C) and total cholesterol(TC) were measured by cholesterol oxidase method; and Gensini scoring system was used to evaluate the degree of coronary artery stenosis. Results The levels of fT3 in both bi-vessel CAD and multi-vessel subgroups were higher than those in control group(t=1.947, 6.415, both P < 0.05). And the level of fT4 in multi-vessel subgroup was also higher than that in control group (t=3.026, P < 0.05). fT3 was an independent risk factor of CAD using Logistic regression model. In addition, fT3 was negatively correlated with Gensini scoring in multiple linear regressions. Gensini scores would increase by 1 as long as the level of fT3 decreases 0.234 pmol/L. Conclusion fT3 level decreased in patients with CAD, and correlated with the severity of CAD. Gensini scores would increase 1 as long as fT3 decreases 0.234 pmol/L, which could be supposed as a sensitive predictor of CAD. -
Key words:
- Thyroid hormones /
- Coronary artery disease /
- Gensini scoring
-
表 1 冠心病冠脉狭窄各组与冠脉无狭窄组基本资料分析
组别 例数 年龄
(x±s,岁)性别
(男/女)吸烟史
(n,%)糖尿病史
(n,%)高血压史
(n,%)脑卒中史
(n,%)fT3
(pmol/L)fT4
(x±s,pmol/L)TSH
(x±s,pmol/L)TC
(x±s,mmol/L)LDL-C
(x±s,mmol/L)HDL-C
(x±s,mmol/L)TG
(mmol/L)FBG
(mmol/L)LVEF
(x±s,%)冠脉无狭窄组 98 61.3±11.2 43/55 17(17.3) 14(14.3) 76(77.6) 14(14.3) 0.68
(4.06~5.49)16.49±3.13 2.87±1.16 4.99±1.13 3.09±0.93 1.13±0.39 0.17
(1.07~2.02)0.72
(4.77~5.63)59.05±5.79 单支病变组 30 65.1±11.3 17/13 9(30.0) 9(30.0) 25(83.3) 7(23.3) 0.65
(3.98~4.75)18.08±2.31 2.58±1.07 4.67±1.45 3.03±1.31 0.99±0.22 0.13
(1.06~1.61)0.75
(4.96~5.87)58.07±5.67 双支病变组 15 66.2±6.9 7月8日 2(13.3) 5(33.3) 12(80.0) 3(20.0) 0.63
(3.77~4.96)17.49±2.72 2.83±1.00 4.63±1.41 2.83±0.92 1.02±0.34 0.14
(0.90~2.23)0.76
(3.96~8.71)56.07±6.97 多支病变组 15 66.5±11.7 11月4日 5(33.3) 6(40.0) 14(93.3) 2(13.3) 0.55
(3.21~3.87)17.81±3.47 3.97±0.93 4.43±0.77 3.97±0.93 0.89±0.18 0.28
(1.17~3.46)0.73
(3.91~5.33)48.53±9.47 注:表中,fT3为游离三碘甲腺原氨酸,fT4为游离甲状腺素,TSH为促甲状腺激素,TC为总胆固醇,TG为三酰甘油,LDL-C为低密度脂蛋白胆固醇,HDL-C为高密度脂蛋白胆固醇,FBG为空腹血糖,LVEF为左心室射血分数。 表 2 冠心病患者危险因素Logistic回归分析
变量 OR(95%CI) P值 模型1 fT3 0.447(0.277~0.723) 0.001 年龄 1.053(1.012~1.096) 0.011 糖尿病史 4.932(1.521~15.997) 0.008 模型2 fT3 0.561(0.312~-1.010) 0.054 糖尿病史 4.422(1.332~-14.682) 0.015 模型3 fT3 0.499(0.231~-1.080) 0.078 模型4 fT3 0.085(0.013~-0.570) 0.011 糖尿病史 13.149(1.154~-149.83) 0.038 注:表中,OR为危险度比值;95%CI为95%可信度区间;fT3为游离三碘甲腺原氨酸。 -
[1] Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med, 2001, 344(7): 501-509. [2] Duntas LH. Thyroid disease and lipids. Thyroid, 2002, 12(4): 287- 293. [3] Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine, 2004, 24(1): 1-13. [4] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983, 51(3): 606. [5] Miura S, Iitaka M, Suzuki S, et al. Decrease in serum levels of thyroid hormone in patients with coronary heart disease. Endocr J, 1996, 43(6): 657-663. [6] Müller B, Tsakiris DA, Roth CB, et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest, 2001, 31(2): 131-137. [7] Pretnar-Oblak J, Sebestjen M, Sabovic M. Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension. Am J Hypertens, 2008, 21(6): 674-678. [8] De Pergola G, Ciampolillo A, Paolotti S, et al. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol(Oxf), 2007, 67(2): 265-269. [9] Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab, 2005, 90(7): 4019-4024. [10] Iqbal A, Figenschau Y, Jorde R. Blood pressure in relation to serum thyrotropin: the Tromso study. J Hum Hypertens, 2006, 20(12): 932-936. [11] Park HT, Cho GJ, Ahn KH, et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas, 2009, 62(3): 301-305. [12] Asvold BO, Vatten LJ, Nilsen TI, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol, 2007, 156(2): 181-186. [13] Dullaart RP, de Vries R, Roozendaal C, et al. Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjects. Clin Endocrinol(Oxf), 2007, 67(5): 668-673. [14] Roos A, Bakker SJ, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab, 2007, 92(2): 491-496. [15] Tatar E, Kircelli F, Asci G, et al. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol, 2011, 6(9): 2240-2246. [16] Coceani M, Iervasi G, Pingitore A, et al. Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol, 2009, 32(7): 380-385. [17] 陈志奎, 胡申江, 刘春霞, 等.冠心病患者的血清甲状腺激素水平.中国内分泌代谢杂志, 2004, 20(2): 143-144.
[18] Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med, 2005, 118(2): 132-136. [19] Iervasi G, Landi P, Raciti M, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 2003, 107(5): 708-713. [20] Ertas F, Kaya H, Soydinc MS. Low serum free triiodothyronine levels are associated with the presence and severity of coronary artery disease in the euthyroid patients: an observational study. Anadolu Kardiyol Derg, 2012, 12(7): 591-596.